{"id":20,"date":"2024-11-27T18:40:20","date_gmt":"2024-11-27T18:40:20","guid":{"rendered":"https:\/\/www.adarx.com\/?page_id=20"},"modified":"2026-09-04T15:22:21","modified_gmt":"2026-09-04T22:22:21","slug":"patients","status":"publish","type":"page","link":"https:\/\/www.adarx.com\/dev\/patients\/","title":{"rendered":"Patients"},"content":{"rendered":"\n

Overview<\/h2>\n\n\n\n
\n\n\n\n

At ADARx, we are committed to better outcomes for patients. We leverage our innovative siRNA therapeutic approach with a goal of providing highly effective and convenient treatments addressing unmet needs across a broad range of diseases including complement-mediated diseases, hereditary angioedema (HAE), thrombotic diseases, obesity and neurodegenerative diseases including Alzheimer\u2019s.<\/p>\n\n\n\n

Patients are at the center of everything we do, and we work with urgency knowing that we have the potential to improve the lives of patients.<\/p>\n\n\n\n<\/div><\/div><\/div>\n\n\n\n

Clinical Trials<\/h2>\n\n\n\n

Advancements in siRNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below<\/p>\n\n\n\n

STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema<\/p>\n\n\n\n

If you are interested, visit this website:<\/strong><\/p>\n\n\n\n

\"stophae-logo\"<\/a><\/figure>\n\n\n\n
\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients<\/p>\n\n\n\n

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers and a Phase 2a, Open-Label Study in Patients with Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324.<\/p>\n\n\n\n

\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease<\/p>\n\n\n\n

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.<\/p>\n\n\n\n

\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy<\/p>\n\n\n\n

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.<\/p>\n\n\n\n

\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients<\/p>\n\n\n\n

The first-in-human Phase 1\/Phase 2a study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).<\/p>\n\n\n\n

\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Phase 1 Study of ADX-626 in Healthy Participants<\/p>\n\n\n\n

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).<\/p>\n\n\n\n

\n
Learn More<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

For Patients<\/h2>\n\n\n\n

ADARx invites patients to consider the possibility of participating in our clinical studies. Your doctor may contact ADARx at info@adarx.com<\/a> to learn more.<\/p>\n\n\n\n

Expanded Access Policy<\/h2>\n\n\n\n

ADARx is committed to advancing siRNA therapeutics for patients with challenging diseases, and we deeply understand the urgency felt by individuals and families seeking every available treatment option. At this time, our development resources are focused on conducting rigorous clinical studies to establish the safety and efficacy of our investigational medicines and to obtain regulatory approval that will enable broader, equitable patient access. Because all available resources, including limited supplies of our investigational products, are dedicated to our ongoing clinical trials, ADARx is not making its unapproved drugs available on an expanded access basis at this time. If you have any questions about ADARx\u2019s expanded access policy, please contact info@adarx.com<\/a> for more information. Although ADARx is not making its drugs available on an expanded access basis at this time, we anticipate acknowledging receipt of any expanded access questions or requests within five business days of receipt.<\/p>\n\n\n\n

Participation in our clinical trials currently represents the only pathway to access ADARx investigational medicines. As our programs advance and we gather additional safety and efficacy data, we will continue to evaluate the feasibility of establishing an Expanded Access Program, and we will update this policy should circumstances change. In the event that we decide to make our products available on an expanded access basis, this policy will be updated with a hyperlink to the relevant expanded access record(s) on clinicaltrials.gov after such records become active.<\/p>\n\n\n\n

We encourage patients to speak with their healthcare provider about clinical trial eligibility. If there is interest in learning more about clinical trials, please have your healthcare provider contact info@adarx.com<\/a> for more information.<\/p>\n\n\n\n

ADARx may revise this expanded access policy at any time. Additionally, the posting of this policy by ADARx shall not serve as a guarantee of access to any specific investigational drug by any individual patient.<\/p>\n","protected":false},"excerpt":{"rendered":"

Overview Clinical Trials Advancements in siRNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema If you are interested, visit this website: Safety, Tolerability, […]<\/p>\n","protected":false},"author":1,"featured_media":113,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-20","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nPatients - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patients - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Overview Clinical Trials Advancements in siRNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema If you are interested, visit this website: Safety, Tolerability, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/patients\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T22:22:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/patients-header.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2009\" \/>\n\t<meta property=\"og:image:height\" content=\"895\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/\",\"name\":\"Patients - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/patients-header.jpg\",\"datePublished\":\"2024-11-27T18:40:20+00:00\",\"dateModified\":\"2026-09-04T22:22:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/patients-header.jpg\",\"contentUrl\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/patients-header.jpg\",\"width\":2009,\"height\":895,\"caption\":\"patients-header\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patients - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Patients - ADARx Pharmaceuticals","og_description":"Overview Clinical Trials Advancements in siRNA medicines would not be possible without participation from patients in clinical trials. Learn more about our ongoing clinical trials below STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema If you are interested, visit this website: Safety, Tolerability, […]","og_url":"https:\/\/www.adarx.com\/dev\/patients\/","og_site_name":"ADARx Pharmaceuticals","article_modified_time":"2026-09-04T22:22:21+00:00","og_image":[{"width":2009,"height":895,"url":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/patients-header.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/patients\/","url":"https:\/\/www.adarx.com\/dev\/patients\/","name":"Patients - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.adarx.com\/dev\/patients\/#primaryimage"},"image":{"@id":"https:\/\/www.adarx.com\/dev\/patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/patients-header.jpg","datePublished":"2024-11-27T18:40:20+00:00","dateModified":"2026-09-04T22:22:21+00:00","breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.adarx.com\/dev\/patients\/#primaryimage","url":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/patients-header.jpg","contentUrl":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/patients-header.jpg","width":2009,"height":895,"caption":"patients-header"},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":24,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/20\/revisions"}],"predecessor-version":[{"id":1028,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/20\/revisions\/1028"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media\/113"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}